Cabergoline NDC 59762-1005

NDC codes

FDA NDC Directory

Product NDC (as listed)59762-1005Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59762-1005Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59762-1005-1	59762100501	8 TABLET in 1 BOTTLE (59762-1005-1)Marketed from Sep 22, 2014

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cabergoline
Generic name (nonproprietary): cabergoline
Active ingredients: Cabergoline — .5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Mylan Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 020664
Marketing start: Sep 22, 2014
Listing expires: Dec 31, 2027
Other FDA classes: Ergolines (Chemical structure)
Identifiers: Product ID 59762-1005_03f16695-e1cd-4d6b-9205-b3d5bf1b7c6cSPL ID 03f16695-e1cd-4d6b-9205-b3d5bf1b7c6cSPL set ID e497366b-a124-4d7f-bd45-a883c392d4bbRxCUI 199703UNII LL60K9J05T
Pharmacologic class: Ergot Derivative

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459762100501 followed by a unit qualifier and the quantity

Package 59762-1005-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 30, 2026.

Indications (excerpt from the label)

CABERGOLINE is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. Limitations of Use Avoid use of CABERGOLINE for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions [see Warnings and Precautions (5.4) ] . CABERGOLINE is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. ( 1 ) Limitations of Use Avoid use of CABERGOLINE for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions. ( 5.4 )…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)